OmniAb, Inc.
OABINASDAQHealthcareBiotechnology
Previous close
$4.33
+$0.03 · +0.70%
OABI company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
37
Expensive
Momentum
62
Gaining
Sentiment
41
Mixed
Risk resilience
46
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteOmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Matthew W. Foehr
- Listed since
- Sep 30, 2021
- Employees
- 89
Market position
Day range
Current $4.33
52-week range
Current $4.33
- Open
- $4.305
- Previous close
- $4.30
- Volume
- 1.85M
- 1.86× average
- Average volume
- 993.64K
- Average daily volume
- Market cap
- 627.73M USD
- Beta
- 1.22
- Market reference 1
- 50-day average
- $2.522
- +71.69% above average
- 200-day average
- $2.0067
- +115.78% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 205.03M USD
- EV / EBITDA
- -4.6×
- Earnings yield
- -30.81%
- Free cash flow yield
- -17.61%
Profitability & efficiency
- Return on equity
- -24.26%
- Return on assets
- -21.53%
- Return on invested capital
- -24.22%
Financial health
- Current ratio
- 4.02×
- Altman Z-score
- 11.54
- Piotroski F-score
- 4 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 18.67M USD | 26.39M USD | 34.16M USD | 59.08M USD | 34.75M USD |
| Cost of goods sold | 22.06M USD | — | — | — | — |
| Gross profit | −3.39M USD | 26.39M USD | 34.16M USD | 59.08M USD | 34.75M USD |
| Research and development | 47.75M USD | 55.11M USD | 56.53M USD | 48.36M USD | 39.23M USD |
| Selling, general, and administrative | 29.22M USD | 30.74M USD | 33.31M USD | 24.9M USD | 16.95M USD |
| Operating expenses | 68.13M USD | 100.89M USD | 103.58M USD | 85.73M USD | 70.36M USD |
| Interest income | 2.66M USD | 3.11M USD | 5.06M USD | 587K USD | — |
| Interest expense | — | — | — | — | 7K USD |
| Depreciation and amortization | 21.75M USD | 23.58M USD | 19.5M USD | 18.25M USD | 16.25M USD |
| Operating income | −71.52M USD | −74.5M USD | −69.42M USD | −26.65M USD | −35.61M USD |
| Net income | −64.78M USD | −62.03M USD | −50.62M USD | −22.33M USD | −27.04M USD |
Company facts updated Aug 24, 2026.
Earnings
- Latest fiscal-year EPS
- -0.57
- FY2025
- Latest fiscal-year revenue
- 18.67M USD
- FY2025 · -29.27% year over year
- Next fiscal-year EPS consensus
- -0.361
- FY2026 · 4 analysts
- Next fiscal-year revenue consensus
- 34.96M USD
- FY2026 · 5 analysts
Annual EPS trend
Reported history and fiscal-year consensus
Annual revenue trend
Reported history and fiscal-year consensus
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$4.00
7.62% downsideRating distribution
9 ratingsRecent analyst actions
OABI peers
ETFs holding OABI
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM11.83M0.01%81.62B USD0.19%$299.96+0.77%
Vanguard Morningstar Total Stock Market ETFVTI4.71M0.00%2.3T USD0.03%$378.24+0.44%
iShares Russell 2000 Value ETFIWN4.36M0.03%14.66B USD0.24%$224.81+0.45%
iShares Biotechnology ETFIBB3.75M0.04%10.75B USD0.44%$213.56+1.29%
Vanguard Extended Market ETFVXF2.75M0.00%93.7B USD0.05%$245.53+0.82%
Schwab U.S. Small-Cap ETFSCHA2.4M0.01%23.1B USD0.03%$34.83+0.52%
iShares Micro-Cap ETFIWC1.64M0.11%1.53B USD0.60%$198.39+1.10%
Vanguard Russell 2000 ETFVTWO1.21M0.01%17.4B USD0.06%$121.25+0.74%iShares Russell 2000 ETFIWM- Market value
- 11.83M
- Weight
- 0.01%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $299.96+0.77%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 4.71M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
iShares Russell 2000 Value ETFIWN- Market value
- 4.36M
- Weight
- 0.03%
- AUM
- 14.66B USD
- Expense ratio
- 0.24%
- Price / 1D
- $224.81+0.45%
iShares Biotechnology ETFIBB- Market value
- 3.75M
- Weight
- 0.04%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $213.56+1.29%
Vanguard Extended Market ETFVXF- Market value
- 2.75M
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
Schwab U.S. Small-Cap ETFSCHA- Market value
- 2.4M
- Weight
- 0.01%
- AUM
- 23.1B USD
- Expense ratio
- 0.03%
- Price / 1D
- $34.83+0.52%
iShares Micro-Cap ETFIWC- Market value
- 1.64M
- Weight
- 0.11%
- AUM
- 1.53B USD
- Expense ratio
- 0.60%
- Price / 1D
- $198.39+1.10%
Vanguard Russell 2000 ETFVTWO- Market value
- 1.21M
- Weight
- 0.01%
- AUM
- 17.4B USD
- Expense ratio
- 0.06%
- Price / 1D
- $121.25+0.74%
Continue in GoAI
Research OABIresearch.disclaimer